Story perspectives

Atwater Malick Cuts Novo Stake Amid Price Drop

1/19/2025

33 5

Summary

Story summary

Atwater Malick LLC decreased its Novo Nordisk A/S stake by 2.8%, now holding 162,228 shares worth $13.96 million.
Novo Nordisk's stock dropped 5.2% to $78.74 due to Medicare price negotiations for drugs like Ozempic and Wegovy.
Analysts continue to recommend a "Buy" rating, with price targets between $79 and $160, indicating mixed market views.
Based in Denmark, Novo Nordisk is a leader in diabetes and obesity treatments, commanding a substantial global market share.

1 of 1

Story summary

Atwater Malick LLC decreased its Novo Nordisk A/S stake by 2.8%, now holding 162,228 shares worth $13.96 million.
Novo Nordisk's stock dropped 5.2% to $78.74 due to Medicare price negotiations for drugs like Ozempic and Wegovy.
Analysts continue to recommend a "Buy" rating, with price targets between $79 and $160, indicating mixed market views.
Based in Denmark, Novo Nordisk is a leader in diabetes and obesity treatments, commanding a substantial global market share.